Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Uterine Cervical Neoplasms 3Lung Neoplasms 3Gliosarcoma 3Glioblastoma 3Carcinoma, Ovarian Epithelial 3Carcinoma, Non-Small-Cell Lung 3Squamous Intraepithelial Lesions 2Central Nervous System Neoplasms 2Breast Neoplasms 2Thrombocytopenia 1Recurrence 1Prostatic Neoplasms 1Prolactinoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Pituitary Neoplasms 1Ovarian Neoplasms 1Oligodendroglioma 1Neoplasms 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1

Interventions

lanreotide 1Temozolomide 1Surveys and Questionnaires 1Solutions 1Radiosurgery 1Microarray Analysis 1Injections 1Early Intervention, Educational 1Diet, Mediterranean 1Diet, Ketogenic 1DNA Methylation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Growth Hormone-Secreting Pituitary Adenoma × DNA Methylation × Clear all
NCT00601289 2020-07-31

Temozolomide in Treating Patients With Invasive Pituitary Tumors

Jonsson Comprehensive Cancer Center

Phase 2 Withdrawn
CNSEndocrine

Adenoma, Basophil, Adenoma, Chromophobe, Adenoma, Acidophil, Pituitary Neoplasms, Prolactinoma, Central Nervous System Neoplasms, Growth Hormone-Secreting Pituitary Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡